Dianthus Therapeutics, Inc. /DE/ (ticker: DNTH) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of DNTH's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. DNTH reported $2.04M in revenue and -$40.83M for the period ending 2025-12-31, with operating cash flow of -$28.86M. Cash and equivalents stood at $627.67M (up 6104.7% year-over-year). Total assets of $1.25B exceed total liabilities of $45.57M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
DNTH Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Dianthus Therapeutics, Inc. /DE/ (DNTH) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.